Cargando…

Availability and Use of Molecular Microbiological and Immunological Tests for the Diagnosis of Tuberculosis in Europe

INTRODUCTION: Currently only limited data exist regarding the availability and clinical use of molecular and immunological tests for tuberculosis (TB) in the European setting. METHODS: Web-based survey of Paediatric-Tuberculosis-Network-European-Trialsgroup (ptbnet) and Tuberculosis-Network-European...

Descripción completa

Detalles Bibliográficos
Autores principales: Tebruegge, Marc, Ritz, Nicole, Koetz, Karsten, Noguera-Julian, Antoni, Seddon, James A., Welch, Steven B., Tsolia, Maria, Kampmann, Beate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055680/
https://www.ncbi.nlm.nih.gov/pubmed/24922084
http://dx.doi.org/10.1371/journal.pone.0099129
_version_ 1782320703678185472
author Tebruegge, Marc
Ritz, Nicole
Koetz, Karsten
Noguera-Julian, Antoni
Seddon, James A.
Welch, Steven B.
Tsolia, Maria
Kampmann, Beate
author_facet Tebruegge, Marc
Ritz, Nicole
Koetz, Karsten
Noguera-Julian, Antoni
Seddon, James A.
Welch, Steven B.
Tsolia, Maria
Kampmann, Beate
author_sort Tebruegge, Marc
collection PubMed
description INTRODUCTION: Currently only limited data exist regarding the availability and clinical use of molecular and immunological tests for tuberculosis (TB) in the European setting. METHODS: Web-based survey of Paediatric-Tuberculosis-Network-European-Trialsgroup (ptbnet) and Tuberculosis-Network-European-Trialsgroup (TBnet) members conducted June to December 2013. Both networks comprise clinicians, microbiologists, epidemiologists and researchers predominately based in Europe. RESULTS: 191 healthcare professionals from 31 European countries participated. Overall, 26.8% of respondents did not have access to the Xpert MTB/RIF assay; only 44.6% had access to the assay in-house. However, a substantial proportion had access to other commercial and/or non-commercial PCR-based assays for TB (68.8% and 31.8%, respectively). Only 6.4% did not have access to any PCR-based assays for TB. A large proportion of participants with access to the Xpert MTB/RIF assay had used it for the analysis of non-respiratory samples [pleural fluid: 36.5%, gastric aspirates: 34.7%, cerebrospinal fluid: 34.7%, stool samples: 4.3%, blood/serum: 2.6%, ‘other samples’ (which included biopsy/tissue samples, lymph node aspirates, joint aspirates and urine samples): 16.5%]. Regarding interferon-gamma release assays, a greater proportion of respondents had access to the QuantiFERON-TB Gold assay (84.7%) than to the T-SPOT.TB assay (52.2%). CONCLUSIONS: Both immunological and molecular TB tests are widely available across Europe. The QuantiFERON-TB Gold assay is more widely used than the T-SPOT.TB assay, which may reflect the difficulties of integrating an ELISPOT assay into the routine laboratory setting. Although Xpert MTB/RIF assays are optimised and solely licensed for the analysis of sputum samples, in clinical practice they are commonly used for non-respiratory samples. Further research is needed to establish how current molecular TB tests impact on patient care and outcome in the routine clinical setting.
format Online
Article
Text
id pubmed-4055680
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40556802014-06-18 Availability and Use of Molecular Microbiological and Immunological Tests for the Diagnosis of Tuberculosis in Europe Tebruegge, Marc Ritz, Nicole Koetz, Karsten Noguera-Julian, Antoni Seddon, James A. Welch, Steven B. Tsolia, Maria Kampmann, Beate PLoS One Research Article INTRODUCTION: Currently only limited data exist regarding the availability and clinical use of molecular and immunological tests for tuberculosis (TB) in the European setting. METHODS: Web-based survey of Paediatric-Tuberculosis-Network-European-Trialsgroup (ptbnet) and Tuberculosis-Network-European-Trialsgroup (TBnet) members conducted June to December 2013. Both networks comprise clinicians, microbiologists, epidemiologists and researchers predominately based in Europe. RESULTS: 191 healthcare professionals from 31 European countries participated. Overall, 26.8% of respondents did not have access to the Xpert MTB/RIF assay; only 44.6% had access to the assay in-house. However, a substantial proportion had access to other commercial and/or non-commercial PCR-based assays for TB (68.8% and 31.8%, respectively). Only 6.4% did not have access to any PCR-based assays for TB. A large proportion of participants with access to the Xpert MTB/RIF assay had used it for the analysis of non-respiratory samples [pleural fluid: 36.5%, gastric aspirates: 34.7%, cerebrospinal fluid: 34.7%, stool samples: 4.3%, blood/serum: 2.6%, ‘other samples’ (which included biopsy/tissue samples, lymph node aspirates, joint aspirates and urine samples): 16.5%]. Regarding interferon-gamma release assays, a greater proportion of respondents had access to the QuantiFERON-TB Gold assay (84.7%) than to the T-SPOT.TB assay (52.2%). CONCLUSIONS: Both immunological and molecular TB tests are widely available across Europe. The QuantiFERON-TB Gold assay is more widely used than the T-SPOT.TB assay, which may reflect the difficulties of integrating an ELISPOT assay into the routine laboratory setting. Although Xpert MTB/RIF assays are optimised and solely licensed for the analysis of sputum samples, in clinical practice they are commonly used for non-respiratory samples. Further research is needed to establish how current molecular TB tests impact on patient care and outcome in the routine clinical setting. Public Library of Science 2014-06-12 /pmc/articles/PMC4055680/ /pubmed/24922084 http://dx.doi.org/10.1371/journal.pone.0099129 Text en © 2014 Tebruegge et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Tebruegge, Marc
Ritz, Nicole
Koetz, Karsten
Noguera-Julian, Antoni
Seddon, James A.
Welch, Steven B.
Tsolia, Maria
Kampmann, Beate
Availability and Use of Molecular Microbiological and Immunological Tests for the Diagnosis of Tuberculosis in Europe
title Availability and Use of Molecular Microbiological and Immunological Tests for the Diagnosis of Tuberculosis in Europe
title_full Availability and Use of Molecular Microbiological and Immunological Tests for the Diagnosis of Tuberculosis in Europe
title_fullStr Availability and Use of Molecular Microbiological and Immunological Tests for the Diagnosis of Tuberculosis in Europe
title_full_unstemmed Availability and Use of Molecular Microbiological and Immunological Tests for the Diagnosis of Tuberculosis in Europe
title_short Availability and Use of Molecular Microbiological and Immunological Tests for the Diagnosis of Tuberculosis in Europe
title_sort availability and use of molecular microbiological and immunological tests for the diagnosis of tuberculosis in europe
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055680/
https://www.ncbi.nlm.nih.gov/pubmed/24922084
http://dx.doi.org/10.1371/journal.pone.0099129
work_keys_str_mv AT tebrueggemarc availabilityanduseofmolecularmicrobiologicalandimmunologicaltestsforthediagnosisoftuberculosisineurope
AT ritznicole availabilityanduseofmolecularmicrobiologicalandimmunologicaltestsforthediagnosisoftuberculosisineurope
AT koetzkarsten availabilityanduseofmolecularmicrobiologicalandimmunologicaltestsforthediagnosisoftuberculosisineurope
AT noguerajulianantoni availabilityanduseofmolecularmicrobiologicalandimmunologicaltestsforthediagnosisoftuberculosisineurope
AT seddonjamesa availabilityanduseofmolecularmicrobiologicalandimmunologicaltestsforthediagnosisoftuberculosisineurope
AT welchstevenb availabilityanduseofmolecularmicrobiologicalandimmunologicaltestsforthediagnosisoftuberculosisineurope
AT tsoliamaria availabilityanduseofmolecularmicrobiologicalandimmunologicaltestsforthediagnosisoftuberculosisineurope
AT kampmannbeate availabilityanduseofmolecularmicrobiologicalandimmunologicaltestsforthediagnosisoftuberculosisineurope